NCT06306196View on ClinicalTrials.gov

Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,040

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Hepatitis E Virus Infection
Interventions
BIOLOGICAL

Hecolin® Recombinant Hepatitis E Vaccine

30㎍/dose, 0.5mL administered intramuscularly

BIOLOGICAL

Isotonic Sodium Chloride injection

0.5mL administered intramuscularly

Trial Locations (3)

Unknown

RECRUITING

MeCRU Clinical Research Unit, Ga-Rankuwa

RECRUITING

Newtown Clinical Research Centre, Johannesburg

RECRUITING

Be Part Research, Paarl

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

International Vaccine Institute

OTHER